News

Article

FDA Approves Drug Product Manufacturing for Samsung BioLogics

Author(s):

Pharmaceutical Technology Editors

Drug product approval from FDA follows previous approvals from European and Japanese authorities.

Samsung BioLogics announced on July 25, 2018 that it has been licensed by FDA to manufacture a monoclonal antibody drug product at its Songdo Plant 1. The company has 16 global approvals for manufacturing drug substance in Plant 1 and 2, and drug products in Plant 1 including two European Medicines Agency drug product approvals and one Pharmaceuticals and Medical Device Agency (Japan) drug product approval. 

In a statement announcing the FDA approval, Samsung BioLogics reported the company expects additional global drug substance and drug product approvals for both Plant 1 and Plant 2 during the second half of 2018.

Source: Samsung Biologics

 

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content
White House | Image Credit: © Zack Frank - stock.adobe.com
August 2nd 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery
If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.
Drug Solutions Podcast: Growth and Advancements in Fill/Finish
August 2nd 2025

Drug Solutions Podcast: Growth and Advancements in Fill/Finish

Felicity Thomas
In this episode, Hanns-Christian Mahler from ten23 Health chats about the advances in fill/finish.
Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com
August 2nd 2025

FDA Changes Opioid Pain Medication Labeling Requirements

Susan Haigney
The changes, required for safety labeling of all opioid drugs, will emphasize the risks with long-term use to combat misuse and addiction.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
August 2nd 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines

Feliza Mirasol
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Resignation concept in a professional office setting | Image Credit: © Jane Kelly - stock.adobe.com
August 2nd 2025

FDA Shake-Up: Vinay Prasad Exits Amid Tumult in Biologics Oversight

Christopher Cole
Prasad’s short FDA tenure brought stricter review standards for gene and COVID vaccines, sparking biotech concern and political backlash.
Silver Spring, MD, USA - June 25, 2022: Closeup of the FDA sign seen at its headquarters campus in Silver Spring, Maryland. FDA is a federal agency of the Department of Health and Human Services. | Image Credit: © Tada Images - stock.adobe.com
August 2nd 2025

3 Reasons FDA Says Quality Investments Are Essential for Drug Manufacturers and Patients

Patrick Lavery
FDA’s latest whitepaper shows how scalable quality management investments in pharma reduce costs, improve reliability, and help prevent drug shortages.